Search

Displaying results 7781 - 7790 of 10000 in total
  1. Drug

    Semapimod

    go.drugbank.com/drugs/DB12094
    Investigational

    Semapimod has been used in trials studying the treatment of Crohn Disease.

    Categories: Analgesics, Non-Narcotic
  2. Drug

    Epratuzumab

    go.drugbank.com/drugs/DB04958
    Investigational

    This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.

  3. Drug

    Relutrigine

    go.drugbank.com/drugs/DB21614
    Investigational

    Relutrigine has a monoisotopic molecular weight of 407.08 Da. … The usage of the INN stem '-trigine' in the name indicates that Relutrigine is a sodium channel blocker, signal transduction modulator.

  4. Drug

    Cinitapride

    go.drugbank.com/drugs/DB08810
    Investigational

    It is marketed in Spain and Mexico.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: 4-Amino-N-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamide
  5. Drug

    Amedalin

    go.drugbank.com/drugs/DB09188
    Experimental

    It has no significant effect on reuptake of serotonin and dopamine and no antihistamine or anticholinergic properties. This drug was never marketed. … Amedalin is a selective norepinephrine reuptake inhibitor developed in the 1970s.

  6. Drug

    Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15683
    ApprovedInvestigational

  7. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries. … M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase.

  8. Drug

    OSI-930

    go.drugbank.com/drugs/DB05913
    Investigational

    OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). … In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung cancer, glioblastoma, colorectal, renal, head and neck, non-small cell lung cancer and gastric cancers

  9. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance

  10. Drug

    Human papillomavirus type 52 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10313
    ApprovedInvestigational

    (VLPs) of the major capsid (L1) protein of HPV Type 52 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs. … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles